As demand for regenerative medicines increases, perspectives on the current cell therapy clinical trial landscape continue to evolve.

As a leading, competitive contract research organization (CRO), we act as a business partner – rather than a vendor – in your drug development process.

Implementing a functional service provider (FSP) model can be complex, which is why we use an implementation lead to launch new projects.

Patient-reported outcomes (PROs) and wearable technologies allow for more comprehensive patient data monitoring, resulting in reduced participant burden.